Eli Lilly aggressively expanded its clinical pipeline through two major deals totaling nearly $11 billion, focusing on circular RNA and immunology. Despite these strategic investments, LLY shares fell 1.28% to close at $1044.67 on February 9.
- The expansion includes a $2.4 billion acquisition of Orna Therapeutics and an $8.5 billion collaboration with Innovent Biologics.
- These moves are designed to sustain growth beyond the company's dominant GLP-1 franchise.
- Analysts linked the share price decline to profit-taking following a recent rally and general weakness across the healthcare sector.